13F Pro

BIOS Capital Management, LP

Institutional InvestorSimilar funds →SEC EDGAR: CIK 1813845
Institutional-grade research for retail investors

13F Reported Value

ⓘ

$52.9M

Holdings

6

Latest Filing

2026-03-31

Filing Quarter

Q1 2026

Portfolio Overview

BIOS Capital Management, LP disclosed 6 positions worth $52.9M in its Form 13F-HR for Q1 2026, led by $ACTU (ACTUATE THERAPEUTICS, INC.) at 52.1% of the equity portfolio, followed by $IRD and $CGTX. The portfolio is most concentrated in Healthcare (100.0% of disclosed assets). All figures are sourced directly from BIOS Capital Management, LP’s Form 13F-HR filing with the SEC under CIK 1813845.

AI Fund Analysis

Stable
ACTU$ACTU
52.1% weight
Held 6 quarters
IRD$IRD
31.7% weight
Held 6 quarters
CGTX$CGTX
8.6% weight
Held 6 quarters
RNTX$RNTX
4.9% weight
Held 6 quarters
LTRN$LTRN
2.2% weight
Held 6 quarters

Sector Allocation

Healthcare

AUM History

Top Equity Holdings by Value

Quarterly Activity — Q1 2026

Click any card to unlock

Top Holdings

AI Quality Scored

Unlock AI quality scores for every holding

32-signal composite ranking on each of BIOS Capital Management, LP's 6 positions.

Showing top 6 of 6 holdings.

Sector Allocation

Healthcare

$52.9M

Full Holdings — BIOS Capital Management, LP (Q1 2026)

All 6 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.

#TickerCompanyValueWeightQoQQuality
1ACTU$ACTUACTUATE THERAPEUTICS, INC.$27.5M52.1%+0%—
2IRD$IRDOpus Genetics, Inc.$16.8M31.7%+0%—
3CGTX$CGTXCOGNITION THERAPEUTICS INC$4.6M8.6%+0%—
4RNTX$RNTXRein Therapeutics, Inc.$2.6M4.9%+17%—
5LTRN$LTRNLantern Pharma Inc.$1.2M2.2%-14%—
6INAB$INABIN8BIO, INC.$248,3510.5%-34%—

Browse Top Institutional Investors

13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.

Berkshire HathawayBridgewater AssociatesCitadel AdvisorsRenaissance TechnologiesTwo Sigma InvestmentsDE Shaw & CoMillennium ManagementAQR Capital ManagementPoint72 Asset ManagementTiger Global ManagementVanguard GroupBlackRock

to search all 8,700+ institutional filers.

Available Analysis

13F Pro tracks comprehensive institutional data for BIOS Capital Management, LP including:

Full 13F portfolio with all holdings
Quarter-over-quarter position changes
Accumulation & distribution patterns
Sector allocation breakdown
Historical portfolio evolution
New positions & complete exits
Concentration analysis
Peer comparison with similar funds
AI-powered portfolio insights

Track BIOS Capital Management, LP's Full Portfolio

See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for BIOS Capital Management, LP and 8,700+ other institutional investors.

View Pricing

Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

AI-Powered Hedge Fund Analysis: BIOS Capital Management, LP

13F Pro is an AI hedge fund tracker and stock research platform. For BIOS Capital Management, LP (SEC CIK: 1813845), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.

Every holding in BIOS Capital Management, LP's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.